+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 128 Actively Recruiting clinical trials

E

Actively Recruiting

This research aims to evaluate the efficacy and safety of rilzabrutinib in adults diagnosed with active Immunoglobulin G4-related disease IgG4-RD. It is a Phase 3, randomized, double-blind, placebo-controlled study that will measure the time to clinical disease flare and other important efficacy and safety outcomes over a 52-week treatment period. The study includes adult participants aged 18 and older who have a confirmed diagnosis of IgG4-RD and active disease in at least one organ. Participants will be randomly assigned to receive either rilzabrutinib tablets or a placebo, both taken orally, over a 52-week double-blind treatment period. The study also includes a screening period of 4 to 6 weeks before treatment, followed by a 2-week follow-up after the treatment phase. An optional open-label extension lasting 108 weeks is available for participants who complete the main study. The total study duration may extend up to 60 weeks for the main phases. Throughout the study, participants will attend up to 16 visits during the main treatment period and additional visits if they join the extension phase. Researchers will monitor disease activity and flare rates using clinical assessments, imaging procedures such as CT, MRI, PET, or ultrasound, laboratory tests, ECGs, and safety evaluations including adverse event monitoring. Outcomes include flare-free rates, disease activity scores, glucocorticoid use, and safety parameters, with follow-up continuing beyond the treatment phase to assess long-term effects.

Age: 18Years +All GendersPhase 3
95 locations
S

Actively Recruiting

Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.

Age: 18Years +All GendersPhase 3
331 locations
P

Actively Recruiting

Researchers are evaluating the safety and tolerability of Efimosfermin Alfa in adults with known or suspected metabolic dysfunction-associated steatohepatitis MASH at fibrosis stages F2 or F3. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand how this drug affects participants with this liver condition. Participants will be randomly assigned to one of three groups receiving Efimosfermin Alfa at dose level 1, Efimosfermin Alfa at dose level 2, or a placebo. The treatment is administered as an injection, and the study will track effects and adverse events over 52 weeks. The study includes multiple assessments, including liver fibrosis measurements and blood tests to monitor liver health and other related factors. During the study, participants will undergo regular evaluations including blood tests, imaging scans, and clinical assessments up to Week 52 to monitor safety, liver function, and fibrosis changes. Researchers will measure treatment-emergent adverse events, laboratory abnormalities, and changes in liver fibrosis and fat content using various biomarkers and imaging techniques. This detailed monitoring helps assess the treatments impact and safety profile throughout the study period.

Age: 18Years - 75YearsAll GendersPhase 3
66 locations
S

Actively Recruiting

Researchers are studying the safety and effectiveness of FLT201, a gene therapy, in adults with Gaucher disease Type 1 who have been on stable enzyme replacement or substrate reduction therapy for at least two years. This Phase 3 study aims to confirm how well FLT201 works and its safety after participants stop their current therapies. Participants will receive a single intravenous infusion of FLT201, which is an advanced gene therapy made from a modified virus vector carrying genetic material. The study is non-randomized and conducted at multiple centers, focusing on this one group receiving the investigational treatment. Throughout the study, participants will be monitored for response to FLT201 over a year to evaluate its effectiveness. Researchers will assess safety and track health outcomes, with the overall study lasting several years. This includes follow-up visits and evaluations to understand long-term impacts of the gene therapy.

Age: 18Years +All GendersPhase 3
32 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.

Age: 18Years +All GendersPhase 3
325 locations
O

Actively Recruiting

Diffuse large B-cell lymphoma DLBCL is the most common and aggressive subtype of non-Hodgkin lymphoma NHL, affecting many patients with rapid tumor growth and symptoms depending on tumor location. This observational study aims to understand the clinical characteristics, treatment patterns, and access to new therapies for patients with DLBCL in the Middle East and Africa region, including both newly diagnosed and relapsed or refractory cases. Participants are grouped into two cohorts those who are newly diagnosed and eligible for treatment, and those who have relapsed or are refractory after at least one prior therapy. The study does not involve experimental treatments but collects information on how patients are treated in real-world settings and explores access to innovative therapies. During the study, patient demographics, disease characteristics, risk profiles, and treatment patterns are documented over 22 months. Researchers will gather data through reviews of medical records and clinical information without administering treatments. The primary goal is to describe first-line and subsequent treatment approaches and to understand patient access to novel therapies for DLBCL.

All AgesAll Genders
21 locations
S

Actively Recruiting

Researchers are studying osivelotor, an oral drug, in adults and adolescents with sickle cell disease SCD. This Phase 23 trial aims to evaluate the safety, tolerability, effectiveness, and how the body processes the drug. The study includes participants with specific SCD types and looks to find the best dose while also comparing the drug against a placebo over 48 weeks. A long-term extension will assess ongoing safety and blood response. The study has three parts. Part A tested safety and dose in adults to find the optimal dose. Part B compares osivelotor to placebo in adults and adolescents over 48 weeks, with adults receiving a loading dose of 300 mg daily for 7 days then 150 mg daily, while adolescent doses will be defined later. An open-label extension allows participants who completed Part B to take osivelotor for up to two years or until it becomes commercially available. Participants will undergo screening to confirm eligibility, including stable hemoglobin levels and SCD history. During the trial, participants receive study medication or placebo and attend regular visits for monitoring. Researchers will assess safety, blood characteristics, and vaso-occlusive crisis events. The study includes careful monitoring of adverse events and blood tests, with a total participation period that may last up to two years for those in the extension phase.

Age: 12Years +All GendersPhase 2Phase 3
80 locations
S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
E

Actively Recruiting

Researchers are studying the effects of AZD0120, an autologous dual-targeting CAR-T therapy aimed at BCMA and CD19, compared with autologous stem cell transplant ASCT in people newly diagnosed with multiple myeloma who are eligible for transplant. This open-label, randomized Phase III trial aims to measure progression-free survival and the rate of minimal residual disease negative complete response over up to 13 years. Participants are assigned to one of two treatment groups. Arm A receives lymphodepletion with cyclophosphamide and fludarabine over three days, followed by a single infusion of AZD0120 CAR-T cells, then up to two years of lenalidomide maintenance therapy. Arm B receives high-dose melphalan conditioning for 24 to 48 hours followed by ASCT and then the same lenalidomide maintenance regimen for up to two years. The study includes a long-term follow-up period lasting up to 15 years after the last AZD0120 infusion. Throughout the study, participants undergo regular monitoring, including assessments of disease progression and response according to established criteria. Researchers evaluate outcomes such as progression-free survival, complete and overall response rates, duration of response, and safety over approximately 13 years. Participants may expect study visits and evaluations aligned with treatment and follow-up schedules to track their health and treatment effects during this extended period.

Age: 18Years - 130YearsAll GendersPhase 3
114 locations
P

Actively Recruiting

Researchers are evaluating efimosfermin alfa in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis MASH and stage F2 or F3 liver fibrosis. The study aims to assess the safety and effectiveness of efimosfermin alfa compared to a placebo in resolving steatohepatitis and improving liver-related clinical outcomes. This Phase 3 trial is randomized, double-blind, and placebo-controlled, focusing on participants with specific liver conditions and metabolic syndrome components. Participants are assigned to one of three groups two groups receive different dose levels of efimosfermin alfa, while the third group receives a placebo. Treatments are given under controlled conditions, and the study follows a parallel design. The trial monitors participants at set intervals over a course of 52 weeks, with some outcomes tracked up to 48 months to evaluate long-term effects on liver fibrosis and steatohepatitis. During the study, participants undergo liver biopsies to confirm diagnosis and assess changes. Researchers evaluate improvements in fibrosis stage, steatohepatitis resolution, and various liver function measurements using imaging and blood tests. Safety is monitored by tracking adverse events and laboratory abnormalities. Quality of life and other health indicators are also assessed throughout the study, which lasts several years to capture both short- and long-term outcomes.

Age: 18Years - 75YearsAll GendersPhase 3
91 locations

1-10 of 128

1